Ginkgo leaf sustained-release tablet with stable release performance
A technology of ginkgo biloba and sustained-release preparations, applied in the field of medicine, can solve the problems of large dosage, complicated process, high cost, etc., and achieve the effects of less administration times, simple process, and small fluctuation of blood drug concentration.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0047] Composition (its proportioning quantity is in parts by weight, and it is also the same when expressing proportioning quantity below):
[0048] Ginkgo biloba extract 120 parts
[0049] Sodium Lauryl Sulfate 15 parts
[0050] Poloxamer 25 parts
[0051] Hypromellose (K4M CR) 55 parts
[0052] Lactose 85 parts
[0053] Microcrystalline cellulose 80 parts
[0054] Micropowder silica gel 20 parts
[0055] Magnesium stearate 6 parts.
[0056] Preparation Process:
[0057] Mix ginkgo biloba extract with sodium lauryl sulfate and poloxamer, then mix with lactose, microcrystalline cellulose, and hypromellose, then add magnesium stearate, micronized silica gel, and mix well. The whole powder is directly compressed into tablets to obtain tablets, each containing 120 mg of ginkgo biloba extract.
[0058] In vitro release test: get this product, according to the release assay method (Chinese Pharmacopoeia version two appendix XD first method in 2000), adopt the first method ...
Embodiment 2
[0063] Element:
[0064] Ginkgo biloba extract 120 parts
[0065] Tween 80 makes 15 servings
[0066] Hypromellose (K15M CR) 25 parts
[0067] Lactose 100 parts
[0068] Microcrystalline cellulose 100 parts
[0069] Micropowder silica gel 20 parts
[0070] Magnesium stearate 6 parts.
[0071] Preparation process: after the Ginkgo biloba extract and Tween 80 are evenly mixed, other excipients are added, mixed evenly, and compressed into tablets to obtain tablets, each containing 120 mg of Ginkgo biloba extract.
[0072] The in vitro release testing method is the same as in Example 1.
[0073] The cumulative release rate of the sustained-release preparation obtained in the present embodiment is as follows:
[0074] time (hours)
Embodiment 3
[0076] Element:
[0077] Ginkgo biloba extract 120 parts
[0078] Docusate sodium 5 parts
[0079] Tween 80 measures 5 servings
[0080] Hypromellose (K4M) 35 parts
[0081] Hypromellose (K15M) 10 parts
[0082] Lactose 125 parts
[0083] Microcrystalline cellulose 130 parts
[0084] Micropowder silica gel 20 parts
[0085] Magnesium stearate 6 parts.
[0086] The preparation process is the same as in Example 2, and the in vitro release test method is the same as in Example 1.
[0087] The cumulative release rate of the sustained-release preparation obtained in the present embodiment is as follows:
[0088] time (hours)
PUM
| Property | Measurement | Unit |
|---|---|---|
| viscosity | aaaaa | aaaaa |
| viscosity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More